Antisense molecules: A new class of drugs

Daniel P Potaczek; Holger Garn; Sebastian D Unger; Harald Renz

doi:10.1016/j.jaci.2015.12.1344

Antisense molecules: A new class of drugs

J Allergy Clin Immunol. 2016 May;137(5):1334-46. doi: 10.1016/j.jaci.2015.12.1344.

Authors

Daniel P Potaczek¹, Holger Garn¹, Sebastian D Unger¹, Harald Renz²

Affiliations

¹ Institute of Laboratory Medicine, Philipps-University Marburg, Marburg, Germany.
² Institute of Laboratory Medicine, Philipps-University Marburg, Marburg, Germany. Electronic address: [email protected].

PMID: 27155029
DOI: 10.1016/j.jaci.2015.12.1344

Abstract

An improved understanding of disease pathogenesis leads to identification of novel therapeutic targets. From a pharmacologic point of view, these can be addressed by small chemical compounds, so-called biologicals (eg, mAbs and recombinant proteins), or by a rather new class of molecule based on the antisense concept. Recently, a new wave of clinical studies exploring antisense strategies is evolving. In addition to cancer, they include predominantly trials on infectious and noninfectious diseases, such as chronic inflammatory and metabolic conditions. This article, based on a systematic PubMed literature search, highlights recent developments in this emerging field.

Keywords: Clinical trial; DNAzyme; antisense; small interfering RNA; therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Eye Diseases / drug therapy
Humans
Inflammation / drug therapy
Metabolic Diseases / drug therapy
Oligonucleotides, Antisense / pharmacology
Oligonucleotides, Antisense / therapeutic use*
Virus Diseases / drug therapy

Substances

Oligonucleotides, Antisense